A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.

Bengt Sorbe,Marianne Graflund,Lisa Nygren,György Horvath,Marie Swahn,Karin Boman,Rene Bangshöj,Margareta Lood,Henric Malmström

A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.

2011

Bengt Sorbe
Marianne Graflund
Lisa Nygren
György Horvath
Marie Swahn
Karin Boman
Rene Bangshöj
Margareta Lood
Henric Malmström

The purpose of this study was to assess the response rate, toxicity, progression-free survival (PFS) and overall survival (OS) in a series of advanced stage ovarian carcinoma patients treated with ...

Keywords:

Cancer
Phases of clinical research
Ovarian cancer
Carboplatin
Carcinoma
Oncology
Every Three Weeks
Internal medicine
Medicine
Docetaxel
Chemotherapy
ovarian carcinoma
Toxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations